AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) published a new CEO Corner segment on December 10, 2025. CEO Thomas Equels discusses the unmet need in pancreatic cancer and the company’s lead therapy Ampligen (rintatolimod).
The segment summarizes Ampligen’s ongoing clinical evaluation in the DURIPANC Phase 1b/2 trial where it is being tested in combination with AstraZeneca’s Imfinzi (durvalumab). The CEO Corner video and comments are now available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – AIM
In the Dec 10 session, AIM declined 2.68%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Investor presentation | Positive | +2.0% | CEO fireside chat on Ampligen clinical and regulatory strategy. |
| Nov 18 | Earnings update | Negative | -7.6% | Q3 2025 results showing low cash, losses and continued cash burn. |
| Nov 10 | Clinical data update | Positive | -6.4% | Phase 2 ovarian cancer trial detailed with 50% ORR versus lower historical ORRs. |
| Nov 04 | Conference abstract | Positive | -20.4% | Late‑breaking SITC abstract acceptance for Ampligen ovarian cancer study. |
| Nov 03 | Patent grant | Positive | -4.3% | European patent granted for Ampligen use in treating Long COVID fatigue. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent AIM news has often been positive on clinical or strategic fronts but followed by negative price reactions, indicating a pattern of good news being sold.
Over the last six weeks, AIM has highlighted multiple developments around Ampligen, including DURIPANC trial updates, ovarian cancer data at the 40th SITC Meeting, and a European patent for Long COVID. An earnings release on Nov 18, 2025 detailed limited cash of $2.4M and ongoing losses. Despite several clinically positive or strategic announcements, the stock frequently declined afterward, framing today’s CEO Corner communication within a backdrop of execution progress but persistent market skepticism.
Key Terms
pancreatic cancer medical
phase 1b/2 medical
clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer
OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website.
In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi® (durvalumab).
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com